Cargando…
Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
BACKGROUND: Continuous administration of levodopa‐carbidopa intestinal gel (carbidopa‐levodopa enteral suspension) through a percutaneous endoscopic gastrojejunostomy is a treatment option for advanced Parkinson disease (PD) patients with motor fluctuations resistant to standard oral medications. Sa...
Autores principales: | Lang, Anthony E., Rodriguez, Ramon L., Boyd, James T., Chouinard, Sylvain, Zadikoff, Cindy, Espay, Alberto J., Slevin, John T., Fernandez, Hubert H., Lew, Mark F., Stein, David A., Odin, Per, Fung, Victor S.C., Klostermann, Fabian, Fasano, Alfonso, Draganov, Peter V., Schmulewitz, Nathan, Robieson, Weining Z., Eaton, Susan, Chatamra, Krai, Benesh, Janet A., Dubow, Jordan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064722/ https://www.ncbi.nlm.nih.gov/pubmed/26695437 http://dx.doi.org/10.1002/mds.26485 |
Ejemplares similares
-
Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease
por: Fernandez, Hubert H, et al.
Publicado: (2016) -
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results
por: Fernandez, Hubert H, et al.
Publicado: (2015) -
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018) -
Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016) -
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)